Xiaomei Leng

Xiaomei Leng

Auto-generated profile, based on publicly available information

Xiaomei Leng

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
WBWei Bai
Wei Bai
HLHuilan Liu
Huilan Liu
LDLei Dou
Lei Dou
YYYunJiao Yang
YunJiao Yang
XLXiaoMei Leng
XiaoMei Leng
XZXiaofeng Zeng
Xiaofeng Zeng

10 February 2023 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
FYFan Yang
Fan Yang
CLChaofan Lu
Chaofan Lu
YWYanhong Wang
Yanhong Wang
HLHuilan Liu
Huilan Liu
XLXiaomei Leng
Xiaomei Leng
XZXiao-Feng Zeng
Xiao-Feng Zeng

15 February 2023 in Trials
Verified
Journal Article
Open access
PDF file
WBWei Bai
Wei Bai
FYFan Yang
Fan Yang
HXHuji Xu
Huji Xu
WWWei Wei
Wei Wei
HLHongbin Li
Hongbin Li
XLXiaomei Leng
Xiaomei Leng
Background: Primary Sjogren’s syndrome (pSS) is a systemic autoimmune disease involving multiple organ systems. The Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway is a key pathway involving the pathogenesis of pSS. Baricitinib, a selective JAK1 and JAK2 inhibitor, has been approved for treatment of active rheumatoid arthritis and reported in treatment of some other autoimmune diseases including systemic lupus erythematosus. We have found that baricitinib might be effective and safe in pSS in a pilot study. However, there is no published clinical evidence of baricitinib in pSS. Hence, we conducted this randomized study to further explore the efficacy and safety of baricitinib in pSS. Methods: This is a multi-center, prospective, open-label, randomized study to compare the efficacy of baricitinib + hydroxychloroquine (HCQ) with HCQ alone in pSS patients. We plan to involve 87 active pSS patients with European League Against Rheumatism pSS disease activity index (ESSDAI) ≥ 5 from eight different tertiary centers in China. Patients will be randomized (2:1) to receive baricitinib 4 mg per day + HCQ 400 mg per day or HCQ 400 mg per day alone. We will switch HCQ to baricitinib + HCQ if the patient in the latter group has no ESSDAI response at week 12. The final evaluation will be at week 24. The primary endpoint is the percentage of ESSDAI response, or minimal clinically important improvement (MCII), which was defined as an improvement of ESSDAI at least three points at week 12. The secondary endpoints include EULAR pSS patient-reported index (ESSPRI) response, change of Physician’s Global Assessment (PGA) score, serological activity parameters, salivary gland function test, and focus score on labial salivary gland biopsy. Discussion: This is the first randomized controlled study to evaluate the clinical efficacy and safety of baricitinib in pSS. We hope that the result of this study can provide more reliable evidence of the efficacy and safety of baricitinib in pSS. Trial registration: ClinicalTrials.gov NCT05016297. Registered on 19 Aug 2021.

22 November 2024 in Rheumatology
Verified
Journal Article
Open access
PDF file
FYFan Yang
Fan Yang
CLChaofan Lu
Chaofan Lu
QPQingqing Pan
Qingqing Pan
RZRui Zhang
Rui Zhang
MYMeng Yang
Meng Yang
XLXiaomei Leng
Xiaomei Leng
As fibroblast-like synoviocyte activation and bone formation are associated with psoriatic arthritis (PsA), positron emission tomography (PET) using the tracers of 68Ga-fibroblast activation protein inhibitor (FAPI) and 18F-sodium fluoride (NaF) may sensitively detect the disease. In this prospective study, we aimed to evaluate the performance of 68Ga-FAPI PET/CT in PsA and to compare it with 18F-NaF PET/CT. Sixteen participants (female 7/16, age 42.31 ± 10.66 years) with PsA were prospectively enrolled and underwent dual-tracer PET/CT, clinical assessment and ultrasonography. PET/CT images were scored for PET-positive lesions at the peripheral joints, entheses, and axial joints. The positivity rate of 68Ga-FAPI in peripheral joints is higher than that in entheses and axial joints (21.84% vs 12.15% vs 0%), whereas high positivity rates of 18F-NaF in peripheral joints, entheses, and axial joints were observed (85.23%, 78.13%, and 75%, respectively). The disease activity score 28 was higher in the PET-positive than in the PET-negative group with 68Ga-FAPI (5.25 ± 1.84 vs 2.55 ± 0.94, p= 0.037), but not with 18F-NaF. Besides, the PET joint count at 68Ga-FAPI PET/CT was positively correlated with the TJC (r = 0.604, p= 0.017), SJC (r = 0.773, p= 0.001), DAS28-CRP (r = 0.556, p= 0.032), PASDAS (r = 0.540, p= 0.038) and PsASon13 (r = 0.701, p= 0.005), while no correlation was observed in 18F-NaF PET/CT. The positivity rates of 68Ga-FAPI- and 18F-NaF PET/CT were different in patients with PsA in peripheral joints, entheses, and axial joints. The extent of joint involvement at 68Ga-FAPI PET/CT correlated with clinical and ultrasound variables as well as disease activity.

9 July 2023 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
CLChaofan Lu
Chaofan Lu
FYFan Yang
Fan Yang
HLHuilan Liu
Huilan Liu
LDLei Dou
Lei Dou
YWYanhong Wang
Yanhong Wang
XZXiao-Feng Zeng
Xiao-Feng Zeng

8 November 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
FYFan Yang
Fan Yang
JTJunwei Tian
Junwei Tian
LPLinyi Peng
Linyi Peng
LZLi Zhang
Li Zhang
JLJia Liu
Jia Liu
XLXiaomei Leng
Xiaomei Leng
Objectives: This study aims to describe clinical characteristics and outcome of thrombotic microangiopathy (TMA) in Chinese patients with systemic lupus erythematosus (SLE), and investigate the risk factors.Methods: We conducted a retrospective single-center cohort and enrolled patients of TMA associated with SLE between January 2015 and December 2018. Demographic characteristics, clinical features, laboratory profiles, therapeutic strategies, and outcomes were collected. The risk factors of TMA in patients with SLE for mortality using multivariate analysis were estimated.Results: A total of 119 patients with a diagnosis of TMA were enrolled within the study period in our center, and SLE was found in 72 (60.5%) patients. The mean age was 29.2 ± 10.1 and 65 (92.3%) were women. Only 15 patients were found with definite causes, the other 57 cases remained with unclear reasons. Sixty-two patients got improved, while 10 patients died after treatment (mortality rate: 13.9%). Compared with the survival group, the deceased group had a higher prevalence of neuropsychiatric manifestations, infection with two or more sites, increased levels of C-reaction protein (CRP) and D-Dimer, and decreased platelet count. Multivariate analysis showed that the decrease of platelet count is the independent risk factor for in-hospital mortality for TMA in patients with SLE. The receiver operating characteristic (ROC) curve analysis displayed that a cutoff value of <18 × 109/L for platelet count could significantly increase the risk of death.Conclusions: Thrombotic microangiopathy often occurs in patients with active SLE with high mortality (13.9%), and thrombocytopenia, especially when the platelet count is lower than 18 × 109/L, is the risk factor for death.